

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Balance Sheets
September 30, 2022, December 31, 2021, and September 30, 2021
(Expressed in Thousands of New Taiwan Dollars)
(Reviewed, Not Audited)

| <u>Assets</u> | | | <u>September 30, 2022</u> | | <u>December 31, 2021</u> | | <u>September 30, 2021</u> | |
|---------------------------|---|------------|---------------------------|------------|--------------------------|------------|---------------------------|------------|
| | | | <u>Amount</u> | <u>%</u> | <u>Amount</u> | <u>%</u> | <u>Amount</u> | <u>%</u> |
| Current assets | | | | | | | | |
| 1100 | Cash and cash equivalents | 6(1) | \$ 406,881 | 3 | \$ 849,035 | 7 | \$ 981,260 | 8 |
| 1136 | Financial assets at amortized cost - current | 6(2) | 485,050 | 4 | 89,149 | 1 | - | - |
| 1150 | Notes receivable, net | 6(3) | 317,739 | 3 | 389,240 | 3 | 292,023 | 2 |
| 1160 | Notes receivable - related parties | 7 | 132,919 | 1 | 97,942 | 1 | 119,758 | 1 |
| 1170 | Accounts receivable, net | 6(3) | 1,591,013 | 13 | 1,537,048 | 12 | 1,535,206 | 12 |
| 1180 | Accounts receivable - related parties | 7 | 30,487 | - | 28,342 | - | 25,892 | - |
| 1200 | Other receivables | | 29,255 | - | 35,408 | - | 36,672 | - |
| 1210 | Other receivables - related parties | 7 | 239,821 | 2 | 227,900 | 2 | 185,205 | 2 |
| 1220 | Current tax assets | | 3,987 | - | 4,871 | - | 1,857 | - |
| 130X | Inventories | 6(4) | 2,509,883 | 20 | 2,266,107 | 18 | 2,356,622 | 19 |
| 1476 | Other financial assets - current | 8 | - | - | 7,908 | - | 12,057 | - |
| 1479 | Other current asset - other | | 94,032 | 1 | 34,095 | - | 32,731 | - |
| 11XX | Total current assets | | <u>5,841,067</u> | <u>47</u> | <u>5,567,045</u> | <u>44</u> | <u>5,579,283</u> | <u>44</u> |
| Non-current assets | | | | | | | | |
| 1517 | Financial assets at fair value through other comprehensive income - non-current | 6(5) | 583,248 | 5 | 1,240,965 | 10 | 1,249,313 | 10 |
| 1550 | Investments accounted for using equity method | 6(6) and 7 | 1,378,118 | 11 | 1,313,133 | 10 | 1,151,017 | 9 |
| 1600 | Property, plant and equipment | 6(7) and 8 | 4,107,174 | 33 | 4,136,266 | 32 | 4,103,575 | 32 |
| 1755 | Right-of-use assets | 6(8) | 129,230 | 1 | 88,930 | 1 | 89,498 | 1 |
| 1760 | Investment property | | 59,135 | - | 58,830 | - | 58,765 | - |
| 1780 | Intangible assets | | 12,955 | - | 15,936 | - | 18,807 | - |
| 1840 | Deferred income tax assets | | 210,097 | 2 | 196,683 | 2 | 229,358 | 2 |
| 1900 | Other non-current assets | 6(9) and 9 | 178,136 | 1 | 169,088 | 1 | 194,106 | 2 |
| 15XX | Total Non-current assets | | <u>6,658,093</u> | <u>53</u> | <u>7,219,831</u> | <u>56</u> | <u>7,094,439</u> | <u>56</u> |
| 1XXX | Total assets | | <u>\$ 12,499,160</u> | <u>100</u> | <u>\$ 12,786,876</u> | <u>100</u> | <u>\$ 12,673,722</u> | <u>100</u> |

(Continued)

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Balance Sheets
September 30, 2022, December 31, 2021, and September 30, 2021
(Expressed in Thousands of New Taiwan Dollars)
(Reviewed, Not Audited)

| Liabilities and Equity | | | September 30, 2022 | | December 31, 2021 | | September 30, 2021 | |
|--|--|--------------|---------------------------|------------|--------------------------|------------|---------------------------|------------|
| | | | Amount | % | Amount | % | Amount | % |
| Current liabilities | | | | | | | | |
| 2100 | Short-term borrowings | 6(10) and 8 | \$ 1,362,511 | 11 | \$ 864,664 | 7 | \$ 878,787 | 7 |
| 2110 | Short-term notes and bills payable | 6(11) | 305,000 | 2 | 231,967 | 2 | 120,000 | 1 |
| 2130 | Contract liabilities - current | 6(19) | 48,523 | - | 43,619 | - | 35,281 | - |
| 2150 | Notes payable | | 3,567 | - | 41,812 | - | 65,735 | 1 |
| 2170 | Accounts payable | 7 | 837,383 | 7 | 757,318 | 6 | 818,210 | 6 |
| 2200 | Other payables | 6(12) | 591,554 | 5 | 660,941 | 5 | 619,296 | 5 |
| 2230 | Current tax liabilities | | 75,036 | 1 | 76,046 | 1 | 60,860 | 1 |
| 2280 | Lease liabilities - current | | 20,679 | - | 14,919 | - | 14,784 | - |
| 2320 | Current portion of long-term debt | 6(13) and 8 | 21,000 | - | 21,000 | - | 21,000 | - |
| 2365 | Refund liabilities - current | 6(19) | 103,944 | 1 | 72,205 | 1 | 78,352 | 1 |
| 2399 | Other current liabilities - other | 7 | 85,793 | 1 | 22,972 | - | 24,659 | - |
| 21XX | Total current liabilities | | <u>3,454,990</u> | <u>28</u> | <u>2,807,463</u> | <u>22</u> | <u>2,736,964</u> | <u>22</u> |
| Non-current liabilities | | | | | | | | |
| 2540 | Long-term borrowings | 6(13) and 8 | 1,416,000 | 11 | 1,844,000 | 14 | 1,936,000 | 15 |
| 2570 | Deferred income tax liabilities | | 170,932 | 1 | 171,657 | 1 | 149,031 | 1 |
| 2580 | Lease liabilities - non-current | | 93,791 | 1 | 57,652 | 1 | 58,370 | 1 |
| 2600 | Other non-current liabilities | 6(14) | 111,349 | 1 | 117,634 | 1 | 153,647 | 1 |
| 25XX | Total non-current liabilities | | <u>1,792,072</u> | <u>14</u> | <u>2,190,943</u> | <u>17</u> | <u>2,297,048</u> | <u>18</u> |
| 2XXX | Total liabilities | | <u>5,247,062</u> | <u>42</u> | <u>4,998,406</u> | <u>39</u> | <u>5,034,012</u> | <u>40</u> |
| Equity attributable to owners of parent | | | | | | | | |
| Share capital | | | | | | | | |
| 3110 | Common stock | 6(15) | 2,980,811 | 24 | 2,980,811 | 23 | 2,980,811 | 23 |
| Capital surplus | | | | | | | | |
| 3200 | Capital surplus | 6(16) | 647,627 | 6 | 646,593 | 6 | 646,000 | 6 |
| Retained earnings | | | | | | | | |
| 3310 | Legal reserve | 6(17) | 724,856 | 6 | 610,012 | 5 | 610,012 | 5 |
| 3320 | Special reserve | | 188,958 | 1 | 188,958 | 1 | 188,958 | 1 |
| 3350 | Unappropriated retained earnings | | 2,838,373 | 23 | 2,818,381 | 22 | 2,628,381 | 21 |
| Other equity | | | | | | | | |
| 3400 | Other equity | 6(18) | (137,084) | (2) | 537,409 | 4 | 578,062 | 4 |
| 3500 | Treasury stock | 6(15) | (28,054) | - | (28,054) | - | (28,054) | - |
| 31XX | Equity attributable to owners of the parent | | <u>7,215,487</u> | <u>58</u> | <u>7,754,110</u> | <u>61</u> | <u>7,604,170</u> | <u>60</u> |
| 36XX | Non-controlling interest | | <u>36,611</u> | <u>-</u> | <u>34,360</u> | <u>-</u> | <u>35,540</u> | <u>-</u> |
| 3XXX | Total equity | | <u>7,252,098</u> | <u>58</u> | <u>7,788,470</u> | <u>61</u> | <u>7,639,710</u> | <u>60</u> |
| Commitments and contingent liabilities | | | | | | | | |
| 3X2X | Total liabilities and equity | 6(7) 7 and 9 | <u>\$ 12,499,160</u> | <u>100</u> | <u>\$ 12,786,876</u> | <u>100</u> | <u>\$ 12,673,722</u> | <u>100</u> |

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements of Comprehensive Income
For the Nine Months Ended September 30, 2022 and 2021
(Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)
(Reviewed, Not Audited)

| Item | | For the three months ended September 30, | | | | For the nine months ended September 30, | | | | |
|------|--|--|--------------|--------|--------------|---|--------------|--------|--------------|-------|
| | | 2022 | | 2021 | | 2022 | | 2021 | | |
| | | Amount | % | Amount | % | Amount | % | Amount | % | |
| 4000 | Operating revenue | 6(19) and 7 | \$ 2,075,680 | 100 | \$ 1,909,525 | 100 | \$ 6,136,603 | 100 | \$ 5,938,250 | 100 |
| 5000 | Operating costs | 6(4)(23) | | | | | | | | |
| | | and 7 | (1,275,653) | (61) | (1,229,298) | (64) | (3,913,806) | (64) | (3,740,149) | (63) |
| 5950 | Gross profit | | 800,027 | 39 | 680,227 | 36 | 2,222,797 | 36 | 2,198,101 | 37 |
| | Operating Expenses | 6(23) | | | | | | | | |
| 6100 | Selling Expenses | | (502,731) | (24) | (456,604) | (24) | (1,394,816) | (23) | (1,397,620) | (24) |
| 6200 | General and administrative expenses | | (75,219) | (4) | (62,948) | (3) | (221,301) | (3) | (204,505) | (3) |
| 6300 | Research and Development Expenses | | (112,731) | (5) | (95,933) | (5) | (319,328) | (5) | (293,847) | (5) |
| 6450 | Expected credit impairment gains (losses) | 12(2) | 4,365 | - | 6,432 | - | 8,403 | - | 4,700 | - |
| 6000 | Total operating expenses | | (686,316) | (33) | (609,053) | (32) | (1,927,042) | (31) | (1,891,272) | (32) |
| 6900 | Operating income | | 113,711 | 6 | 71,174 | 4 | 295,755 | 5 | 306,829 | 5 |
| | Non-operating income and expenses | | | | | | | | | |
| 7100 | Interest income | 6(20) and 7 | 2,138 | - | 3,703 | - | 6,826 | - | 12,250 | - |
| 7010 | Other income | 6(21) | 10,284 | 1 | 48,779 | 3 | 29,776 | 1 | 60,196 | 1 |
| 7020 | Other gains and losses | 6(22) | 5,791 | - | (1,183) | - | 14,205 | - | (10,252) | - |
| 7050 | Finance cost | 6(24) | (10,709) | (1) | (8,276) | - | (28,650) | - | (27,461) | - |
| 7060 | Share of profit of associates and joint ventures accounted for using equity method | 6(6) | 40,155 | 2 | 46,716 | 2 | 144,561 | 2 | 129,073 | 2 |
| 7000 | Total non-operating income and expenses | | 47,659 | 2 | 89,739 | 5 | 166,718 | 3 | 163,806 | 3 |
| 7900 | Income before income tax | | 161,370 | 8 | 160,913 | 9 | 462,473 | 8 | 470,635 | 8 |
| 7950 | Income tax expense | 6(25) | (34,500) | (2) | (31,481) | (2) | (90,007) | (2) | (107,742) | (2) |
| 8200 | Net income | | \$ 126,870 | 6 | \$ 129,432 | 7 | \$ 372,466 | 6 | \$ 362,893 | 6 |

(Continue)

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements of Comprehensive Income
For the Nine Months Ended September 30, 2022 and 2021
(Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)
(Reviewed, Not Audited)

| Item | For the three months ended September 30, | | | | For the nine months ended September 30, | | | | | |
|---|---|----------|-------------|------|---|----|--------------|-------|--------------|----|
| | 2022 | | 2021 | | 2022 | | 2021 | | | |
| | Amount | % | Amount | % | Amount | % | Amount | % | | |
| Other comprehensive income | | | | | | | | | | |
| Components of other comprehensive income that will not be reclassified to profit or loss | | | | | | | | | | |
| 8316 | Unrealized gains from investments in equity instruments measured at fair value through other comprehensive income | 6(5)(18) | | | | | | | | |
| | | | (\$ 85,761) | (4) | \$ 135,611 | 7 | (\$ 677,253) | (11) | \$ 965,144 | 16 |
| 8310 | Other comprehensive income that will not be reclassified to profit or loss | | (85,761) | (4) | 135,611 | 7 | (677,253) | (11) | 965,144 | 16 |
| Components of other comprehensive income that will be reclassified to profit or loss | | | | | | | | | | |
| 8361 | Exchange differences on translation of foreign operations | | 11,573 | - | (704) | - | 42,288 | 1 | (20,172) | - |
| 8370 | Share of other comprehensive loss of associates and joint ventures accounted for using equity method | | (648) | - | (558) | - | 1,475 | - | (967) | - |
| 8399 | Income tax related to items that may be reclassified | 6(25) | (2,315) | - | 140 | - | (8,458) | - | 4,034 | - |
| 8360 | Other comprehensive loss that will be reclassified to profit or loss | | 8,610 | - | (1,122) | - | 35,305 | 1 | (17,105) | - |
| 8300 | Total other comprehensive income for the period | | (\$ 77,151) | (4) | \$ 134,489 | 7 | (\$ 641,948) | (10) | \$ 948,039 | 16 |
| 8500 | Total comprehensive income for the period | | \$ 49,719 | 2 | \$ 263,921 | 14 | (\$ 269,482) | (4) | \$ 1,310,932 | 22 |
| Net income (loss) attributable to: | | | | | | | | | | |
| 8610 | Shareholders of the parent | | \$ 126,787 | 6 | \$ 128,842 | 7 | \$ 370,564 | 6 | \$ 362,535 | 6 |
| 8620 | Non-controlling interests | | 83 | - | 590 | - | 1,902 | - | 358 | - |
| | | | \$ 126,870 | 6 | \$ 129,432 | 7 | \$ 372,466 | 6 | \$ 362,893 | 6 |
| Total comprehensive income (loss) attributable to: | | | | | | | | | | |
| 8710 | Shareholders of the parent | | \$ 49,636 | 2 | \$ 263,331 | 14 | (\$ 271,384) | (4) | \$ 1,310,574 | 22 |
| 8720 | Non-controlling interests | | 83 | - | 590 | - | 1,902 | - | 358 | - |
| | | | \$ 49,719 | 2 | \$ 263,921 | 14 | (\$ 269,482) | (4) | \$ 1,310,932 | 22 |
| Earnings per share | | | | | | | | | | |
| 9750 | Basic earnings per share | 6(26) | \$ 0.43 | | 0.43 | | \$ 1.25 | | \$ 1.22 | |
| 9850 | Diluted earnings per share | | \$ 0.43 | | 0.43 | | \$ 1.24 | | \$ 1.21 | |

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statement of Changes in Equity
For the Nine Months Ended September 30, 2022 and 2021
(Expressed in Thousands of New Taiwan Dollars)
(Reviewed, Not Audited)

| | Equity attributable to owners of the parent | | | | | | | | | | | | |
|--|---|----------------------------------|----------------------------------|---|-------------------|--------------------|--|--|--|--------------------|--------------------|---------------------------------|--------------------|
| | Capital surplus | | | | Retained earnings | | | | Other equity interest | | | | |
| | Share capital - common stock | Additional paid-in capital | Treasury stock transaction | Changes in ownership interests in subsidiaries | Legal reserve | Special reserve | Unappropriated retained earnings | Exchange differences on translation of foreign operations | Unrealized gain (losses) on financial assets measured at fair value through other comprehensi ve Income | Treasury stock | Total | Non- controlling interest | Total equity |
| <u>Nine months ended September 30, 2021</u> | | | | | | | | | | | | | |
| Balance at January 1, 2021 | \$ 2,980,811 | \$578,416 | \$66,240 | \$ 1,344 | \$535,449 | \$188,958 | \$2,042,582 | (\$ 85,549) | \$311,480 | (\$ 28,054) | \$6,591,677 | \$ 35,182 | \$6,626,859 |
| Net income | - | - | - | - | - | - | 362,535 | - | - | - | 362,535 | 358 | 362,893 |
| Other comprehensive income (loss) | 6(5)(18) | - | - | - | - | - | - | (17,105) | 965,144 | - | 948,039 | - | 948,039 |
| Total comprehensive income (loss) | - | - | - | - | - | - | 362,535 | (17,105) | 965,144 | - | 1,310,574 | 358 | 1,310,932 |
| Appropriations of 2020 earnings | 6(17) | - | - | - | - | - | - | - | - | - | - | - | - |
| Legal reserve | - | - | - | - | 74,563 | - | (74,563) | - | - | - | - | - | - |
| Cash dividends | - | - | - | - | - | - | (298,081) | - | - | - | (298,081) | - | (298,081) |
| Disposal of equity instruments investments measured at fair value through other comprehensive income | 6(5)(18) (25) | - | - | - | - | - | 595,908 | - | (595,908) | - | - | - | - |
| Balance at September 30, 2021 | \$ 2,980,811 | \$578,416 | \$66,240 | \$ 1,344 | \$610,012 | \$188,958 | \$2,628,381 | (\$102,654) | \$680,716 | (\$ 28,054) | \$7,604,170 | \$ 35,540 | \$7,639,710 |
| <u>Nine months ended September 30, 2022</u> | | | | | | | | | | | | | |
| Balance at January 1, 2022 | \$ 2,980,811 | \$578,416 | \$66,833 | \$ 1,344 | \$610,012 | \$188,958 | \$2,818,381 | (\$ 93,704) | \$631,113 | (\$ 28,054) | \$7,754,110 | \$ 34,360 | \$7,788,470 |
| Net income | - | - | - | - | - | - | 370,564 | - | - | - | 370,564 | 1,902 | 372,466 |
| Other comprehensive income (loss) | 6(5)(18) | - | - | - | - | - | - | 35,305 | (677,253) | - | (641,948) | - | (641,948) |
| Total comprehensive income (loss) | - | - | - | - | - | - | 370,564 | 35,305 | (677,253) | - | (271,384) | 1,902 | (269,482) |
| Appropriations of 2021 earnings | 6(17) | - | - | - | - | - | - | - | - | - | - | - | - |
| Legal reserve | - | - | - | - | 114,844 | - | (114,844) | - | - | - | - | - | - |
| Cash dividends | - | - | - | - | - | - | (268,273) | - | - | - | (268,273) | - | (268,273) |
| Changes in ownership interests in subsidiaries | - | - | - | 500 | - | - | - | - | - | - | 500 | - | 500 |
| Cash dividends which Subsidiary obtained from the Parent company | - | - | 534 | - | - | - | - | - | - | - | 534 | - | 534 |
| Disposal of equity instruments investments measured at fair value through other comprehensive income | 6(5)(18) (25) | - | - | - | - | - | 32,545 | - | (32,545) | - | - | - | - |
| Changes in Minority Interest | - | - | - | - | - | - | - | - | - | - | - | 349 | 349 |
| Balance at September 30, 2022 | \$ 2,980,811 | \$578,416 | \$67,367 | \$ 1,844 | \$724,856 | \$188,958 | \$2,838,373 | (\$ 58,399) | (\$ 78,685) | (\$ 28,054) | \$7,215,487 | \$ 36,611 | \$7,252,098 |

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Cash Flows
For the Nine Months Ended September 30, 2022 and 2021
(Expressed in Thousands of New Taiwan Dollars)
(Reviewed, Not Audited)

| | For the nine months ended September 30, | |
|--|--|-------------|
| | 2022 | 2021 |
| Cash flows from operating activities | | |
| Income before income tax | \$ 462,473 | \$ 470,635 |
| Adjustments | | |
| Adjustments to reconcile profit (loss) | | |
| Depreciation | 6(7)(8)(23) 212,812 | 198,216 |
| Amortization | 6(23) 4,913 | 9,849 |
| Expected credit impairment gains | 12(2) (8,403) (| (4,700) |
| Allowance for sales discounts | 27,084 (| (16,505) |
| Interest expense | 6(24) 28,650 | 27,461 |
| Interest income | 6(20) (6,826) (| (12,250) |
| Dividend income | 6(5)(21) (8,834) (| (5,291) |
| Net gain of financial assets and liabilities at fair value through profit or loss | 6(22) (13,164) | - |
| Share of profit of associates and joint ventures accounted for using equity method | 6(6) (144,561) (| (129,073) |
| Gain on disposal of property, plant and equipment | 6(22) 145 (| (259) |
| Changes in operating assets and liabilities | | |
| Changes in operating assets | | |
| Acquisition of financial assets at fair value through profit or loss | (383,828) | - |
| Notes Receivable (including related party) | 36,524 | 27,307 |
| Accounts Receivable (including related party) | (56,110) | 165,950 |
| Other Receivable (including related party) | 55,768 | 51,836 |
| Inventories | (255,205) | 38,374 |
| Other current assets | (59,937) | 17,932 |
| Changes in operating liabilities | | |
| Contract liabilities | 4,904 (| (36,810) |
| Notes payable | (38,245) | 65,735 |
| Accounts payable | 72,483 (| (124,784) |
| Other payable | (75,843) (| (94,561) |
| Refund liability | 31,739 | 4,840 |
| Other current liabilities | 62,821 (| (1,647) |
| Other non-current liabilities | (6,967) (| (13,679) |
| Cash (outflow) inflow generated from operations | (57,607) | 638,576 |
| Interest received | 6,826 | 12,250 |
| Interest paid | (28,564) (| (28,127) |
| Income tax paid | (91,492) (| (124,614) |
| Dividend received | 92,258 | 77,669 |
| Net cash flows from operating activities | (78,579) | 575,754 |

(Continue)

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Cash Flows
For the Nine Months Ended September 30, 2022 and 2021
(Expressed in Thousands of New Taiwan Dollars)
(Reviewed, Not Audited)

| | For the nine months ended September 30, | |
|---|--|-------------|
| | 2022 | 2021 |
| <u>Cash flows from investing activities</u> | | |
| Increase in financing receivable | (\$ 45,000) | \$ - |
| Decrease in financial assets at amortized cost | - | 400 |
| Decrease (Increase) in restricted deposit (listed under other current financial assets) | 7,908 | (12,057) |
| Acquisition of financial assets at fair value through other comprehensive income 6(5) | (178,729) | (412,827) |
| Proceeds from disposal of financial assets at fair value through other comprehensive income 6(5) | 157,483 | 861,011 |
| Proceeds from capital reduction of financial assets at fair value through other comprehensive income 6(5) | 3,000 | 9,000 |
| Acquisition of investments accounted for using equity method 6(6) | (2,264) | (131,826) |
| Acquisition of property, plant and equipment 6(27) | (196,735) | (147,694) |
| Proceeds from disposal of property, plant and equipment | 106 | 1,821 |
| Acquisition of intangible assets | (14) | (51) |
| Decrease (Increase) in refundable deposits | 16,908 | (27,690) |
| Decrease in other non-current assets | 5,484 | 5,925 |
| Net cash flows (outflow) inflow from investing activities | (231,853) | 146,012 |
| <u>Cash flows from financing activities</u> | | |
| Increase (Decrease) in short-term borrowings | 497,847 | (264,496) |
| Increase (Decrease) in short-term notes and bills payable | 73,033 | (90,000) |
| Repayment of the principal portion of lease liabilities | (14,025) | (10,963) |
| Proceeds from long-term borrowings | 936,000 | 300,000 |
| Repayments of long-term borrowings | (1,364,000) | (410,000) |
| Increase in guarantee deposits received | (1,951) | 5,468 |
| Cash dividends paid 6(17) | (268,273) | (298,081) |
| Change in non-controlling interests | 349 | - |
| Net cash flows used in financing activities | (141,020) | (768,072) |
| Effect of exchange rate changes | 9,298 | (6,673) |
| Net increase in cash and cash equivalents | (442,154) | (52,979) |
| Cash and cash equivalents at beginning of period | 849,035 | 1,034,239 |
| Cash and cash equivalents at end of period | \$ 406,881 | \$ 981,260 |